(Q38048579)

27 August 2017

title

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy (English)

1 reference

27 August 2017

3

Marc Ladanyi

1 reference

27 August 2017

Alexander Drilon

1

1 reference

27 August 2017

Natasha Rekhtman

series ordinal

2

1 reference

27 August 2017

Paul Paik

series ordinal

4

1 reference

27 August 2017

publication date

1 October 2012

1 reference

Lancet Oncology Commission

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

e418-26

1 reference

27 August 2017

cites work

Pathology of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Striking changes in smoking behaviour and lung cancer incidence by histological type in Southeast Netherlands, 1960–1991

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Clinicopathologic features of peripheral squamous cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Management of Pancoast tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Comprehensive histologic analysis of ALK-rearranged lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Genetics of preneoplasia: lessons from lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

The molecular biology of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Natural history of bronchial preinvasive lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Expression profiling defines a recurrence signature in lung squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Evidence that SOX2 overexpression is oncogenic in the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

AIS is an oncogene amplified in squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

PIK3CA mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

PIK3CA mutations and copy number gains in human lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

PIK3CA mutation and amplification in human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Fibroblast growth factor signalling: from development to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Somatic mutations of the protein kinase gene family in human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970291-7

7 January 2021

10.1016/S1470-2045(12)70291-7

Identifiers

DOI

1 reference

27 August 2017

1 reference